BIOCENTURY’s Emerging Company Profile Spot Bio describes a non-viral approach to deliver full-length genes to muscle using extracellular vesicles, with investigational work moving into investigator-led testing. The profile frames the program as an alternative to viral vectors for Duchenne muscular dystrophy (DMD). The company’s platform targets full-length gene delivery, which is a notable challenge for many existing therapies due to vector capacity constraints and safety considerations. The update also points to upcoming ischemic injury-related work as the next indication focus within investigator-led evaluation. For the DMD landscape, evading viral delivery constraints—while maintaining adequate in vivo expression and durability—remains one of the key technical hurdles. As the field watches for clinical translation benchmarks such as expression levels, functional endpoints and immune response management, EV-based approaches could compete for differentiation if early results are supportive.